已收录 268921 条政策
 政策提纲
  • 暂无提纲
Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma
[摘要] BackgroundThis study aimmed to evaluate the expression of p53-inducible RR small subunit 2 homologue (p53R2) in Lung sarcomatoid carcinoma (LSC) and its association with clinicopathological parameters and prognosis.MethodsIn this study, clinicopathological factors and prognostic significance of the expression of p53R2 was investigated by immunohistochemistry (IHC) in 100 cases of LSC.ResultsThe results showed that the expression of p53R2 was significantly correlated with clinical stage (P<0.05). But there was no statistically correlation with gender, age, smoking, tumor size, pT stage, pN stage, pM stage, therapy and relapse. Kaplan-Meier analysis revealed that the expression of p53R2, clinical stage, pT stage, pN stage, pM stage and tumor size were closely related to patients’ survival, and the analysis also revealed that patients with low expression of p53R2 had a longer overall survival than that with high expression (Mean overall survival: 84.8 months vs. 34.7 months, P<0.05). Further multivariate analysis indicated that the expression of p53R2 was identified as an independent prognostic factor in the prediction of the overall survival for patients with LSC (HR = 3.217, P<0.05).ConclusionsThe expression of p53R2 was inversely associated with the proliferation and progression of LSC, and the results indicated that the high expression of p53R2 was an independent factor for unfavorable prognosis of patients with LSC.
[发布日期] 2017-12-15 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Lung sarcomatoid carcinoma;p53R2;Immunohistochemistry;Prognosis [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文